Acobiom remarked by Biotech Finances

Precision Medicine - Biomarkers & Diagnostics

Acobiom remarked by Biotech Finances

Biotech Finances

BioTech Finances – 10/12/2015

After 16 years of R&D, Acobiom is now able to predict that its companion diagnostic tests could be soon commercialized. Before that, the Montpellier-based company must complete a series of clinical trials evaluating the predictive efficacy of its tests in pancreatic cancer and Alzheimer’s disease.
To finance this crucial step, the company, which looks for €1.5M, has chosen the crowdfunding , by which a call for investment of 500 K€ has just been issued online.

More information (in French) : Biotech Finances Article